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Abstract
Background: Recently, we and other researchers reported that brain metabolic disorders are implicated in
Alzheimer’s disease (AD), a progressive, devastating and incurable neurodegenerative disease. Hence, novel
therapeutic approaches are urgently needed to explore potential and novel therapeutic targets/agents for the
treatment of AD. The neuronal adiponectin receptor 1 (AdipoR1) is an emerging potential target for intervention in
metabolic-associated AD. We aimed to validate this hypothesis and explore in-depth the therapeutic effects of an
osmotin-derived adiponectin-mimetic novel nonapeptide (Os-pep) on metabolic-associated AD.
Methods: We used an Os-pep dosage regimen (5 μg/g, i.p., on alternating days for 45 days) for APP/PS1 in amyloid
β oligomer-injected, transgenic adiponectin knockout (Adipo−/−) and AdipoR1 knockdown mice. After behavioral
studies, brain tissues were subjected to biochemical and immunohistochemical analyses. In separate cohorts of
mice, electrophysiolocal and Golgi staining experiments were performed. To validate the in vivo studies, we used
human APP Swedish (swe)/Indiana (ind)-overexpressing neuroblastoma SH-SY5Y cells, which were subjected to
knockdown of AdipoR1 and APMK with siRNAs, treated with Os-pep and other conditions as per the mechanistic
approach, and we proceeded to perform further biochemical analyses.
Results: Our in vitro and in vivo results show that Os-pep has good safety and neuroprotection profiles and crosses
the blood-brain barrier. We found reduced levels of neuronal AdipoR1 in human AD brain tissue. Os-pep stimulates
AdipoR1 and its downstream target, AMP-activated protein kinase (AMPK) signaling, in AD and Adipo−/− mice.
Mechanistically, in all of the in vivo and in vitro studies, Os-pep rescued aberrant neuronal metabolism by reducing
neuronal insulin resistance and activated downstream insulin signaling through regulation of AdipoR1/AMPK
signaling to consequently improve the memory functions of the AD and Adipo−/− mice, which was associated
with improved synaptic function and long-term potentiation via an AdipoR1-dependent mechanism.
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Conclusion: Our findings show that Os-pep activates AdipoR1/AMPK signaling and regulates neuronal insulin
resistance and insulin signaling, which subsequently rescues memory deficits in AD and adiponectin-deficient
models. Taken together, the results indicate that Os-pep, as an adiponectin-mimetic novel nonapeptide, is a
valuable and promising potential therapeutic candidate to treat aberrant brain metabolism associated with AD and
other neurodegenerative diseases.
Keywords: Alzheimer’s disease (AD), Brain metabolic disorders, Neuronal adiponectin receptor 1 (AdipoR1),
Adiponectin-mimetic novel nonapeptide (Os-pep), AdipoR1/AMPK signaling, Neuronal insulin resistance, Insulin
signaling, Synaptic and memory deficits
Background
Neurodegenerative disorders have become one of the
greatest challenges and threats to our society because
the incidence of these diseases is high in the middle-age
and elderly populations. Despite the huge advancement
in the health sciences, no therapeutics are available for
most neurodegenerative diseases [1, 2]. Currently, the
most important and debilitating neurodegenerative dis-
eases are Alzheimer’s disease (AD), Parkinson’s disease
(PD), and amyotrophic lateral sclerosis (ALS). In all
these neurodegenerative diseases, AD is a prime focus
for researchers and clinicians, as recent statistical data
on AD reported that globally, more than 50 million indi-
viduals are affected with AD, and this number will triple
by 2050. The worldwide cost of AD is approximately
one trillion dollars annually, which will reach two trillion
by the year 2030 [3]. Therefore, it is of the utmost im-
portance to reveal the underlying mechanisms and ex-
plore potential novel therapeutic targets/agents for the
treatment of AD. Recently, researchers have shown great
interest in brain metabolic disorders in neurodegenera-
tive diseases, and studies have suggested that aberrant
brain metabolism plays a role in the disease-modifying
effects of effective therapeutic substances against neuro-
degenerative diseases such as AD [4, 5]. Several estab-
lished studies have reported that impaired insulin
activities and neuronal insulin resistance are associated
with AD pathologies, while regulation of these factors
prevents AD [6–10]. Among brain metabolic perturba-
tions that regulate neuronal insulin resistance and insu-
lin signaling, the signaling of adiponectin and its
receptor are among the most recent and indispensable
research areas. These signaling pathways have been al-
tered in the brain and implicated in metabolic-associated
neurological disorders, and they may be a contributing
risk factor for AD and other neurodegenerative diseases.
Subjects with adiponectin deficiency developed insulin
resistance in the brain and impaired downstream insulin
signaling, leading to AD pathology. Adiponectin has
been reported to function as an anti-diabetic, insulin-
sensitizing, anti-inflammatory and antioxidant agent and
to provide protection against metabolic-associated AD
[11–16]. Waragai et al reported the reduction of adipo-
nectin in AD patients and suggested that reduced adipo-
nectin signaling is involved in AD [17]. Importantly,
adiponectin signaling through AdipoR1 has beneficial ef-
fects on brain metabolism via AMP-activated protein
kinase (AMPK) activation and is consequently impli-
cated in the regulation of energy balance and metabol-
ism as well as multiple other functions, including
sensitization of the insulin receptor signaling pathway,
stimulation of mitochondria biogenesis, and suppression
of inflammation [18–22]. Hence, adiponectin is an inter-
esting endogenous therapeutic candidate for the preven-
tion of metabolic-associated neurodegenerative diseases
such as AD [14–16, 23], and future studies should inves-
tigate mimetics of adiponectin that will also act as adipo-
nectin receptor agonists because the conversion of full-
length adiponectin into an effective drug is limited due
to its size. However, there have been several recent re-
ports that the adiponectin paradox associated with other
chronic diseases might be involved in the pathogenesis
of AD. In other experimental approaches and studies,
adiponectin has been shown to be detrimental in condi-
tions such as chronic heart and chronic kidney diseases,
which gives rise to the adiponectin paradox [24–28]. Re-
cently, epidemiological and research studies have shown
that high serum levels of adiponectin are associated with
low skeletal muscle mass, low muscle density, and poor
physical functioning, which are ultimately implicated in
disability and mortality [29–31]. In contrast, in the brain,
adiponectin is protective against central nervous system
(CNS)-neurotoxic agents and conditions such as 1-
methyl-4-phenyl-pyridinium (MPP+), kainic acid acid-
induced excitotoxicity, in vitro amyloid beta (Aβ)-in-
duced toxicity and synuclein-induced neurodegeneration
[22, 32–35]. Adiponectin reduces Aβ oligomer (AβO)-
mediated neuroinflammation [36]. Additionally, our
group discovered the biological and therapeutic effects
of osmotin, a plant protein and homologue of adiponec-
tin [37, 38]. Osmotin was protective in Aβ and trans-
genic AD mouse models [37–40]. We also confirmed
that osmotin acts as an anti-inflammatory, anti-diabetic
and anti-obesity agent [41, 42]. Therefore, adiponectin-
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based mimetic therapeutic approaches should be closely
investigated for all relevant conditions and experimental
systems. Of note, we aimed to test the therapeutic effect
of an adiponectin-mimetic nonapeptide (C-T-Q-G-P-C-
G-P-T (Os-pep)) in early-stage AD mouse models as
well as in adiponectin-deficient mice, which is a model
that was recently found to show AD pathology.
Several ligands for adiponectin receptors have been re-
ported, including osmotin, which reduces AD pathology
[16, 37–41]. However, osmotin has faced the same prob-
lems and limitations as adiponectin; due to its large size,
osmotin has been limited in its efficacy in translational
studies. Therefore, as a translational strategy, we ex-
tended the research approach by utilizing the osmotin-
based small adiponectin-mimetic Os-pep, which is a very
structurally stable peptide that interacts with the adipo-
nectin recognition site on AdipoR1 and shows similar
activity as adiponectin and osmotin [37, 43–45]. Consid-
ering the evidence that Os-pep mimics adiponectin, Os-
pep may also have significant potential therapeutic value
for the prevention of metabolic-associated AD. It has
been recently reported that aberrant adiponectin and
AdipoR1/AMPK signaling are associated with impaired
insulin signaling and brain insulin resistance in AD-
associated pathology [14–16]. Furthermore, recent stud-
ies have highlighted the mechanistic and potential thera-
peutic effects of adiponectin and adiporon, which are
stimulators of adiponectin receptors, on AD through the
activation of metabolic cascades such as the AdipoR1/
AMPK and downstream insulin signaling pathways [14–
17, 22]. Herein, we hypothesize that novel Os-pep acts
as an adiponectin-mimetic peptide to activate AdipoR1/
AMPK signaling and subsequently rescue aberrant neur-
onal metabolism by reducing neuronal insulin resistance
and activating downstream insulin signaling, which leads
to improvements in synaptic and memory functions in
AD and adiponectin knockout (Adipo−/−) mice.
Materials & methods
We purchased the custom-synthesized 9-amino acid Os-
pep from Peptron (Yuseong-daero, Daejeon, South
Korea), which synthesized and characterized the Os-pep
according to previously published protocols [44]. The
purity (98%) of the peptide was analyzed and character-
ized using reverse-phase HPLC. Further, some materials
and methods are described in the supplementary
material.
Mouse genotyping and grouping and optimization of the
dosage regimen of Os-pep
To optimize and analyze the toxicity and effective dose
of Os-pep, we performed a separate group of studies
using wild-type (WT) male C57BL/6 N mice to examine
the toxicity of Os-pep in vivo. The WT mice were
rearranged into 5 groups (n = 5 mice/group). Os-pep
was administered in bolus dosages of 10, 20, 30, 40 and
50mg/kg in normal saline to the respective groups, and
the Veh-injected mice received the same amount of nor-
mal saline as WT mice. We checked for signs of sys-
temic toxicity, such as head tilt, tremor, abnormal
physical activity and squinting, for 1 week in WT mice
that had been treated with i.p. bolus doses of Os-pep
(10, 20, 30, 40 and 50mg/kg).
Male transgenic adiponectin-deficient (Adipo−/−)
and double transgenic (APPswe, PSENdE9) 85Dbo/
Mmjax amyloid precursor protein and presenilin 1
(APP/PS1) AD mice were purchased from the Jackson
Laboratory (Bar Harbor, ME). WT C57BL/6 N male
mice of the same age were purchased from Samtako
Bio (South Korea). The mice were kept in the univer-
sity animal housing facility under a 12-h (h)/12-h
light/dark cycle at 23 °C in 60 ± 10% humidity with
free access to water and food. Ten-month-old AβO-
injected and APP/PS1 mice and 18-month-old
Adipo−/− mice were carried to the specified injection
and behavioral room and allowed to acclimate for a
few days. AβO or vehicle (Veh) (normal saline) was
injected as previously described [38]. Seven days after
the intracerebroventricular (i.c.v.) AβO and Veh injec-
tions, the mice were divided into the respective
groups: mice that received normal saline (Veh only)
by an intraperitoneal (i.p.) injection (control), mice
that received normal saline (Veh only) by the i.c.v.
route (sham), mice that received AβO by the i.c.v.
route (AβO), mice that received AβO by the i.c.v.
route that were also treated with Os-pep (AβO +Os-
pep) and mice treated with Os-pep alone (Os-pep).
The remaining transgenic and WT mice were grouped
as follows: (1) Veh-injected WT, (2) Veh-injected APP/
PS1, and (3) Os-pep-treated APP/PS1 mice. The
Adipo−/− mice were grouped as follows: (1) Veh-injected
WT, (2) Veh-injected Adipo−/−, and (3) Os-pep-treated
Adipo−/− mice. The grouping and treatment of high-fat
diet (HFD)-fed animals and the animals used for phar-
macokinetic studies are described in the supplementary
material.
Os-pep was dissolved in double-deionized distilled
water and then prepared in normal saline to obtain
the final administered concentration. The AβO, APP/
PS1, Adipo−/− and WT mice were injected i.p. with
Os-pep at a dosage of 5 μg/g on alternating days for
45 days. WT, Veh-injected transgenic-APP/PS1 and
Adipo−/− mice were injected with the same volume of
double-deionized water and normal saline. The WT
control and sham mice as well as the Veh-injected
AβO, APP/PS1, Adipo−/− and HFD mice received the
same volume of double-deionized distilled water or
normal saline.
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Generation of AdipoR1 knock down mice
In a separate cohort of study, we used the polyethyleni-
mine (PEI)-based scramble shRNA and functional
shRNA mediating knockdown of AdipoR1 genes in the
AβO-injected mice as previously described [21].
Behavioral studies
To evaluate the learning and memory functions of the
mice, we performed the Morris water maze (MWM) and
Y-maze tests. After completion of the Os-pep dosage
regimen, behavioral studies were performed on AβO-
injected, AβO-injected and scramble and functional Adi-
poR1 shRNA-treated, APP/PS1 and Adipo−/− mice (n =
13/group) using the MWM and Y-maze tests. Notably,
the separate groups of APP/PS1 and Adipo−/− mice (n =
5–6/group) used for the LTP assay were also subjected
to behavioral analyses. The mice were randomly se-
lected, and the operators were unaware of the genotype
and treatment details for the behavioral study. The
MWM and Y-maze tests were performed as previously
described [38, 39].
Electrophysiology experiments
A separate group of animals were used for the in vitro
electrophysiology analysis. The APP/PS1 and Adipo−/−
mice received i.p. injections of 5 μg/g Os-pep on alter-
nating days for 45 days. The WT and Veh-injected APP/
PS1 and Adipo−/− mice received the same volume of bi-
deionized distilled water and normal saline, respectively
(n = 5–6/group). After the dosage regimen was adminis-
tered, the mice were subjected to behavioral tests. Then,
the mice were anesthetized with isoflurane, and the
brains were rapidly cooled via transcardial perfusion
with ice-cold sucrose artificial cerebrospinal fluid (CSF).
The brains were removed and placed in ice-cold sucrose
artificial CSF. Coronal slices were prepared and incu-
bated in artificial CSF at 35 °C for 30 min for recovery.
The slices were then incubated with artificial CSF at
room temperature (23 °C–25 °C) for 1–4 h before being
placed in the recording chamber for the experiments.
The standard artificial CSF contained (mM): 119 NaCl,
2.5 KCl, 2.5 CaCl2, 1.3 MgSO4, 1.0 NaH2PO4, 26.2
NaH2CO3, 11.0 glucose, 2.0 Na pyruvate, and 1.0 Na as-
corbate saturated with 95% O2/5% CO2. The sucrose
artificial CSF contained (mM): 198 sucrose, 2.5 KCl, 1
NaH2PO4, 26.2 NaHCO3, 11 glucose, 2.0 Na pyruvate,
and 1.0 Na ascorbate saturated with 95% O2/5% CO2.
All experiments were conducted at 27 °C–29 °C. For
electrophysiological experiments, pipette electrodes with
3–6MΩ resistance were used, and whole-cell recordings
were obtained from neurons using infrared (IR)-differen-
tial interference contrast (DIC) optical guidance. The
CA3 and DG regions were excised immediately before
the LTP experiments to isolate the CA1 lesion. Stimuli
were applied to the Schaffer-collateral (SC) pathway
using a concentric bipolar electrode located 100–200
mM from the soma of the recorded cell. The whole-cell
recording solution comprised (mM): 135 Cs methanesul-
fonate, 8 NaCl, 10 HEPES, 0.5 EGTA, 4Mg-ATP, 0.3
Na-GTP and 5 QX-315 Cl (pH 7.25 with CsOH, 285
mOsm). Cells were maintained at − 70 mV during re-
cordings unless indicated otherwise. Recordings were
collected using an Axopatch ID (Molecular Devices,
Sunnyvale, CA) and were digitized at 10 KHz and fil-
tered at 2 KHz. The input resistance and series resist-
ance were monitored continuously during the
recordings. The test stimulation in all EPSC experiments
was set to 0.1 Hz and was 0.2 ms in duration, and its in-
tensity (100–900 μA) was adjusted to induce EPSCs with
amplitudes ranging from 50 to 100 pA at a holding po-
tential of − 70 mV. In the LTP experiments, the baseline
EPSCs were measured for 3 min prior to the introduc-
tion of the paired stimuli (2 Hz, 2 min stimulus and
postsynaptic depolarization to 0 mV). After the introduc-
tion of the paired stimuli (2 Hz, 2 min stimulus and
postsynaptic depolarization to 0 mV), EPSCs were mea-
sured every 10 s for 30 min.
Similarly, in another separate group of studies, normal
mice were used for the in vitro electrophysiology ana-
lysis. The AβO-injected, AβO-injected and scramble
shRNA-treated, and AβO-injected mice with shRNA-
mediated silencing of the AdipoR1 gene received i.p. in-
jections of 5 μg/g Os-pep on alternating days for 45 days.
The control (Veh-injected) and AβO-injected mice re-
ceived the same volume of bi-deionized distilled water
and normal saline, respectively (n = 5–6/group). After
the dosage regimen was administered, the mice were
subjected to behavioral tests. Furthermore, to investigate
the CA1 circuit via the Schaffer collateral (SC) input in
the hippocampus, hippocampal brain slices (400 mM-
thick) were prepared from adult mice. Briefly, after the
mice were anesthetized with isoflurane, the brain was
rapidly cooled via transcardiac perfusion with ice-cold
sucrose artificial cerebrospinal fluid (aCSF). The brain
was removed and placed in ice-cold sucrose aCSF. Cor-
onal slices were prepared and were incubated in aCSF at
35 °C for 30 min to allow recovery. Slices were then in-
cubated in artificial CSF at room temperature (23 °C–
25 °C) for 1–4 h before being placed in the recording
chamber for experiments. The standard aCSF contained
(mM): 124 NaCl, 2.5 KCl, 2.5 CaCl2, 1.3 MgSO4, 1.0
NaH2PO4, 26.2 NaH2CO3, 11 glucose, 2 Na pyruvate,
and 1 Na ascorbate saturated with 95% O2/5% CO2. The
sucrose aCSF contained (mM): 195.5 sucrose, 2.5 KCl,
2.5 CaCl2, 1.3 MgSO4, 1 NaH2PO4, 26.2 NaHCO3, 11
glucose, 2 Na pyruvate, and 1 Na ascorbate saturated
with 95% O2/5% CO2. All experiments were conducted
at 27 °C – 29 °C. For the electrophysiological
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experiments, pipette electrodes with 3–6MΩ resistance
were used, and whole-cell recordings were obtained
from neurons under visual guidance using infrared (IR)-
differential interference contrast (DIC) optics. The CA3
and DG regions were removed immediately prior to
starting the LTP (long-term potentiation) experiments
to isolate the CA1 lesions. Stimuli were applied to the
Schaffer collateral (SC) pathway. Field excitatory post-
synaptic potentials (fEPSPs) were recorded in the CA1
stratum radiatum by using an extracellular glass pipette
(3–5MΩ) filled with aCSF. Schaffer collateral/commis-
sural fibers in the stratum radiatum were stimulated
using a concentric bipolar electrode placed 200–300 μm
away from the recording pipette. The test stimulation in
all fEPSP experiments was performed at 0.1 Hz and was
0.2 ms in duration. For long-term potentiation (LTP), a
voltage that elicited 50% of the maximum fEPSP was
used. Baseline synaptic responses were recorded for 20
min, and then LTP was induced by two high-frequency
stimulation trains (100 Hz, 1 s duration) separated by a
20 s intertrain interval. Recordings were made every 30 s
for 2 h using an Axopatch 1D amplifier (Molecular De-
vices, Sunnyvale, CA) and were digitized at 10 KHz and
filtered at 2 KHz with Digidata 1322A and pClamp 9.0
software (Molecular Devices, Sunnyvale, CA).
Human APPswe/ind plasmid
The human APPswe/ind gene in the pCAX mammalian
expression vector with transcriptional control under the
SV-40 promoter/enhancer was obtained from Addgene;
this sequence was deposited in the APP repository by
Dennis Solkoe (Plasmid 30,145). The plasmid was ampli-
fied in the bacterial strain DH5alpha in Luria-Bertani
media with 50 μg/ml ampicillin. The plasmid was puri-
fied with the Qiagen Plasmid Midi Kit (Cat # 12143) and
confirmed by restriction digestion with the EcoRV re-
striction enzyme.
Human neuroblastoma SH-SY5Y cells cultured with
overexpression of the human APPswe/ind plasmid, siRNA
plasmid and drug treatment
Human neuroblastoma SH-SY5Y cells were seeded (in
6-well culture plates for immunoblotting and in chamber
slides for immunofluorescence) in DMEM (Dulbecco’s
modified Eagle medium) containing 10% fetal bovine
serum (FBS) and 1% antibiotics (penicillin-streptomycin)
and incubated at 37 °C in humidified air containing 5%
CO2. Once the cells reached 70–80% confluence, the
cells were transfected using the pCAX vector containing
the APPswe/ind gene using Lipofectamine 3000 (Life
Technologies) according to the provider’s protocols.
AdipoR1 siRNA (h) (SC-60123) and AMPK siRNA (h)
(SC-45312) (Santa Cruz Biotechnology, Inc.) were used
at a concentration of 10 μM per transfection and
expressed for 72 h according to the manufacturer’s
protocol (Santa Cruz Biotechnology, Inc.). A negative
siRNA (Ambion, Thermo Fisher Scientific) was used as
a control. Seventy-two hours after the transfections, the
cells were exposed to Os-pep (10 μM) for 12 h and then
subjected to immunoblotting and immunofluorescence
analyses.
However, in the case of drug treatment, SH-SY5Y cells
(2 × 104/ml) were cultured in 35-mm dishes in DMEM
containing FBS (10%) and antibiotics (1%) at 37 °C in
humidified air containing 5% CO2. After reaching 70%
confluence, the SH-SY5Y cells were treated with AβO
(1 μM), AβO (1 μM) +Os-pep (10 μM), Os-pep (10 μM),
or DMSO (0.01%) as a control for 12 h and subjected to
immunoblot and immunofluorescence analyses.
Immunoblotting assaypyramidal neuronal
The protein concentrations of the homogenates of
mouse brain tissue and cell lysates in vitro were mea-
sured using a Bio-Rad protein assay kit (Bio-Rad Labora-
tories, Hercules, CA), and immunoblotting was
performed as we previously described [38], using pri-
mary antibodies (detailed information described in the
supplementary Table 1). Western blotting membranes
have been cut prior to original western blot images and
original western blot images are available at supplemen-
tary material.
Confocal microscopy and stereological analyses
Human postmortem paraffin-embedded human brain
tissue from healthy aged patients and AD aged patients
of the same age were obtained from the Department of
Pathology, Case Western Reserve University School of
Medicine, USA. Human brain tissue samples (10 μm-
thick sections) on gelatin-coated slides were deparaffi-
nized three times with absolute xylene (5 min for each
wash) and rehydrated with graded ethyl alcohol (100 to
70%). After deparaffinization of the human brain tissue
sections, samples were prepared from the mouse brain
as we previously described [38], and chamber slides con-
taining cells were washed twice with phosphate-buffered
saline (PBS) (0.01M) for 10 min. After washing, the
slides containing samples were incubated for 1 h with
2% normal serum as a blocking solution and 0.3% Triton
X-100 in PBS. After blocking, the slides were incubated
with primary antibodies (rabbit-p-IRS-1 (Ser 636) and
mouse Aβ (B4) from Santa Cruz Biotechnology, Dallas,
TX, USA) and rabbit AdipoR1 (Abcam) diluted 1:100 in
blocking solution overnight at 4 °C. After primary anti-
body incubation, the sections were washed twice for 5
min each and incubated for 2 h with tetramethylrhoda-
mine isothiocyanate (TRITC)/fluorescein isothiocyanate
(FITC)-conjugated secondary antibody (1:50) from Santa
Cruz Biotechnology, Inc. Furthermore, following
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incubation with the TRITC/FITC-conjugated antibody
(1:50), the slides were incubated overnight with the sec-
ond required primary antibody. Following incubation
with the second primary antibody, the sections were in-
cubated with another secondary antibody (FITC/TRITC-
conjugated (1:50)) for 2 h at room temperature. Cover-
slips were mounted with DAPI along with Dako fluores-
cent mounting medium (Molecular Probe, Eugene, OR).
The double immunofluorescence and single immuno-
fluorescence confocal images were captured through a
laser confocal microscope (FV10-ASW 3.1 Viewer,
Olympus, Tokyo, Japan). Five images per section (tissue)
were captured (by an operator blinded to the experimen-
tal groups) from every respective group. Next, the real
confocal images were converted to tagged image file for-
mat (TIF). The quantification of the immunofluores-
cence intensity in the same region of the cortex/total
area and hippocampus/total area in the TIF images for
all groups was performed using ImageJ software with the
method described below. The TIF image background
was optimized according to the threshold intensity, and
the immunofluorescence intensity was analyzed at the
specified threshold intensity for all groups and was
expressed as the integrated density of the samples rela-
tive to that of the control.
Golgi staining and morphological analyses of
hippocampal pyramidal neuronal cells
In a separate cohort of studies, we performed Golgi
staining and morphological analysis of hippocampal pyr-
amidal neuronal cells and were investigated as accord-
ingly our previous protocol [40].
Data and statistical analyses
Histograms and graphs were generated using GraphPad
Prism 5 (GraphPad Software, San Diego, CA). The cu-
mulative probability curves of mEPSCs were calculated
using the Clampfit 9.0 software and GraphPad Prism 4.
Statistical analyses were performed using one-way/two-
way analysis of variance (ANOVA) followed by two-
tailed independent Student’s t-test, Bonferroni’s multiple
comparisons test or Tukey’s post hoc test, as applicable,
for comparisons among the groups. The data are pre-
sented as the means ± SEM of the three independent ex-
periments. The escape latencies in the behavioral tests
were analyzed using a two-way ANOVA, with training
days as the repeated measurements. The operators and
investigators who performed the behavioral, biochemical,
immunohistochemical and the electrophysiological as-
says and the quantitative analyses thereof were blinded
to the dosage regimen and grouping of animals, as well
as to the in vitro experimental drug treatments and
grouping. The number of animals/human tissue per ex-
periment and the number of experiments per group in
the in vivo and in vitro experiments are presented in
each section and panel of the figure legend. Statistical
significance = P < 0.05. * Significantly different compared
with the WT Veh-injected group; # significantly differ-
ent compared with the AβO-injected, Veh-injected APP/
PS1, Adipo−/− and HFD mice. For all in vitro results,
comparisons among groups are indicated by bars.
Results
Os-pep activated AdipoR1/AMPK signaling both in in vitro
and in vivo AD models and Adipo−/− mice
Remarkable studies have reported reduced neuronal
AdipoR1 levels in in vitro and in vivo AD models [21,
39, 40]. Furthermore, our study and other interesting
and compelling studies reported that neuronal AdipoR1
suppression is associated with metabolic stress, which
leads to AD pathology and memory impairment [13–15,
21, 46, 47]. Therefore, we aimed to investigate neuronal
AdipoR1 and its downstream effector p-AMPK, a key
energy sensor marker involved in metabolic stress, in
human APP Swedish (swe)/Indiana (ind)-overexpressing
SH-SY5Y cells and AβO-exposed SH-SY5Y cells in vitro
AD models. Consistently, we observed reduced Adi-
poR1/p-AMPK levels in AβO-exposed and human
APPswe/ind-overexpressing SH-SY5Y cells. We ob-
served that the use of the optimized concentration
(10 μM) of Os-pep significantly increased neuronal Adi-
poR1/p-AMPK signaling in AβO-treated and human
APPswe/ind-overexpressing SH-SY5Y cells (Fig. S1a,b).
Next, through immunofluorescence staining, we ob-
served that Os-pep (10 μM) significantly increased neur-
onal AdipoR1 immunoreactivity in AβO-exposed SH-
SY5Y cells (Fig. S1c). Furthermore, to confirm the im-
portance of AdipoR1 as a potential target for AD, we an-
alyzed human brain samples from aged healthy and AD
patients via confocal microscopy and interestingly found
reduced AdipoR1 levels in the cortical and hippocampal
regions of AD human brains compared to those in aged
healthy human brains (Fig. 1a). Next, we optimized the
Os-pep dosage regimen for in vivo studies and adminis-
tered Os-pep (5 μg/g, i.p., on alternating days for 45
days) to mice subjected to AβO injection. Notably, Os-
pep significantly increased AdipoR1/p-AMPK signaling
in the AβO-injected mice compared with that in the
AβO-injected mice without Os-pep treatment. We also
noted that chronic Os-pep treatment alone (5 μg/g, i.p.,
on alternating days for 45 days) did not induce any un-
desirable effects even though it provided beneficial ef-
fects by activating AdipoR1/−pAMPK signaling (Fig. 1b).
Next, to extend our approach in a more rigorous
AD in vivo model, we administered Os-pep (5 μg/g, i.p.,
on alternating days for 45 days) to APP/PS1 mice, which
is an established transgenic AD model. Interestingly, we
found that Os-pep remarkably increased AdipoR1/p-
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AMPK signaling in the APP/PS1 group compared to that
in the Veh-treated APP/PS1 mice (Fig. 1c). Furthermore,
it has been recently shown that Adipo−/− mice exhibit
aberrant AdipoR1/AMPK signaling, neuronal insulin re-
sistance and AD pathology [14–16]. Here, we also used
Adipo−/− mice to verify our hypothesis and the
adiponectin-mimetic activity of Os-pep. Notably, we ob-
served reduced levels of AdipoR1/AMPK in the Veh-
injected Adipo−/− mice. However, the administration of
the Os-pep dosage (5 μg/g, i.p., on alternating days for
45 days) to Adipo−/− mice significantly increased Adi-
poR1/AMPK levels compared to those in the group
without Os-pep treatment (Fig. 1d). To validate the
Western blotting results, we performed confocal micros-
copy. We observed that Os-pep administration to APP/
PS1 and Adipo−/− mice significantly increased AdipoR1
immunofluorescence reactivity in brain tissues (Fig. 1e,f).
As a supplement to immunoblotting and confocal mi-
croscopy, we performed AdipoR1 ELISA and AMPK im-
munoassays using mouse brain homogenates. Based on
the AdipoR1 ELISA and AMPK assay results, AdipoR1
and AMPK levels were significantly lower in the Veh-
injected APP/PS1 and Adipo−/− mice than in the control
WT Veh-treated mice. Notably, Os-pep remarkably en-
hanced AdipoR1/AMPK expression in APP/PS1 and
Adipo−/− mice compared to those in Veh-injected APP/
Fig. 1 Os-pep stimulated AdipoR1/p-AMPK signaling in in vivo AD models and Adipo−/− mice (a) The AdipoR1 immunofluorescence reactivity in
the normal aged and AD aged patients’ brain tissue (AdipoR1; Green, DAPI, Blue). Magnified 40X. Scale bar = 50 μm. The data are indicated as the
± SEM for n = 5 human brain per group and the number of independent experiments = 3. Significance = ***p < 0.001; student’s t test (b-d)
Immunoblotting and quantification of AdipoR1 and p-AMPK/total-AMPK expression in the brain tissue of AβO, APP/PS1 and Adipo−/− mice. The
data are expressed as the means ± SEM for the indicated proteins in vivo (n = 8 mice/group) and the number of independent experiments = 3.
Significance = ***p < 0.001; ###p < 0.001; One-way ANOVA followed by Turkey’s post hoc test. ns, indicated that there is no significant difference
among the control, sham and Os-pep treated groups (e, f) Immunofluorescence staining for AdipoR1 (red: TRITC and blue: DAPI) in the cortices
and hippocampi of the APP/PS1 and Adipo−/− mice respectively. The data are indicated as the ± SEM for n = 5 mice per group, and the number
of independent experiments = 3. Magnification: 40X. Scale bar = 50 μm. Significance = ***p < 0.001; ###p < 0.001; One-way ANOVA followed by
Turkey’s post hoc test. (g-j) Histograms present ELISA and immunoassay results for the AdipoR1 and AMPK levels respectively, in vivo brain
homogenates of APP/PS1 and Adipo−/− mice. ELISA and immunoassay data are expressed as the means ± SEM for the indicated proteins in vivo
(n = 8 mice/group), and the number of independent experiments = 3. Significance = ***p < 0.001; ###p < 0.001; One-way ANOVA followed by
Turkey’s post hoc test
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PS1 and Adipo−/− mice (Fig. 1g-j). Next, to determine
the mechanism, we treated APPswe/ind-overexpressing
SH-SY5Y cells with Os-pep (10 μM) with or without
AdipoR1 siRNA. Interestingly, we found a reduction in
AdipoR1 in the APPswe/ind-overexpressing SH-SY5Y
cells, which was reversed by Os-pep, leading to a signifi-
cant increase in AdipoR1; however, the levels of Adi-
poR1 and its downstream target p-AMPK were further
decreased in the APPswe/ind-overexpressing SH-SY5Y
cells upon AdipoR1 knockdown (Fig. 2a, b). We further
performed AdipoR1 ELISA and AMPK immunoassays
using the cell lysate samples. Based on the AdipoR1
ELISA and AMPK assay results, AdipoR1 and AMPK ex-
pression levels were significantly reduced in neuronal
SH-SY5Y cells overexpressing APPswe/ind. Os-pep re-
markably enhanced AdipoR1/AMPK expression in SH-
SY5Y cells overexpressing APPswe/ind. However, when
AdipoR1 expression was knocked down in SH-SY5Y
cells, the interaction of Os-pep with AdipoR1 decreased,
and Os-pep did not promote the stimulation of Adi-
poR1/AMPK signaling, validating that Os-pep acts via
AdipoR1 and activates AMPK signaling (Fig. 2c, d).
Based on results from previous studies [43–45] and our
rigorous in vivo and in vitro results described above, Os-
pep functions as an adiponectin mimetic and activates
AdipoR1/AMPK signaling.
Os-pep rescued neuronal insulin resistance and activated
downstream insulin signaling via AdipoR1/AMPK
signaling
Numerous studies have reported the role of aberrant neur-
onal insulin resistance in brain metabolism, which is associ-
ated with AD. Neuronal insulin resistance instigated by
hyperphosphorylation of IRS-1 at the Ser636/312/307 residues
and downregulation of p-IRS-1Tyr 632 has been associated
with AD pathology and reported in Aβ and APP/PS1
mouse AD models as well as HFD and Adipo−/− mice [8,
9, 14–16, 21, 48]. Concomitantly, we also observed in-
creased levels of p-IRS-1 Ser636/312/307 and reduced levels of
p-IRS-1Tyr 632 in the in the Veh-treated AβO-treated, APP/
PS1 and Adipo−/− and HFD mice. Intriguingly, Os-pep
treatment (5 μg/g, i.p., on alternating days for 45 days) re-
versed these effects, significantly reducing the increase in p-
IRS-1Ser636/312 levels and significantly increasing the p-IRS-
1Tyr 632 levels in the AβO-treated, APP/PS1, Adipo−/− and
HFD mice compared with those in the Veh-treated AβO-
treated, APP/PS1, Adipo−/− and HFD mice, respectively
(Fig. 3a-c, Fig. S2). Furthermore, double immunofluores-
cence images indicated that Os-pep reduced the colocaliza-
tion of the immunofluorescence reactivity of Aβ and p-IRS-
1Ser636 in the APP/PS1 mice (Fig. 3d). We intended to verify
whether Os-pep regulates neuronal insulin resistance
through AdipoR1. Therefore, we used AdipoR1 siRNA to
determine the mechanism by which Os-pep reduced
neuronal insulin resistance in AD models. When we
knocked down AdipoR1, Os-pep did not downregulate p-
IRS-1Ser636/312 in the APPswe/ind-overexpressing SH-SY5Y
cells (Fig. 3e). Furthermore, Os-pep treatment (5 μg/g, i.p.,
on alternating days for 45 days) regulated the levels of vari-
ous biochemical parameters associated with metabolic dis-
orders and AD in the serum of both APP/PS1, HFD and
Adipo−/− mice (Fig. S3a-d; Fig. S4a-d). We also observed a
smaller fold-increase in the body weight of the Os-pep-
treated APP/PS1 HFD and Adipo−/− mice compared with
that of the Veh-treated APP/PS1, HFD and Adipo−/− mice
(Fig. 3e; Fig. S4e). Moreover, Western blotting was per-
formed to assess the role of Os-pep in the important p-
PI3K/Akt/GSK3β (Ser 9) pathway, which is downstream of
insulin signaling, in the AβO-treated, APP/PS1 and
Adipo−/− mice. Os-pep treatment (5 μg/g, i.p., on alternat-
ing days for 45 days) reversed the reduction of p-PI3K/Akt/
GSK3β (Ser 9) levels in the AβO-treated, APP/PS1 and
Adipo−/− mice compared with that in the Veh-treated
AβO-treated, APP/PS1 and Adipo−/− mice, respectively
(Fig. 4a-c). Several compelling studies have shown that acti-
vation of AMPK plays a vital role in the activation of down-
stream insulin signaling [9–11, 14–16]. As we showed that
Os-pep activated AMPK signaling, we used AMPK siRNA
to determine the mechanism by which Os-pep regulated
downstream insulin signaling in the AD model. Os-pep
treatment did not upregulate the p-IRS-1Tyr 632 and p-
PI3K/Akt/GSK3β (Ser 9) pathways in human APPswe/ind-
transfected neuronal SH-SY5Y cells with AMPK knock-
down using AMPK siRNA, suggesting that Os-pep treat-
ment plays a key role in triggering AdipoR1 activation and
downstream p-AMPK signaling and, consequently, in the
regulation of insulin signaling in AD models (Fig. 4d). Hu-
man APPswe/ind-transfected neuronal SH-SY5Y cells with
insulin resistance were exposed to a high insulin concentra-
tion (1 μM) (SH-SY5YIR) to determine the mechanism
underlying the insulin-sensitizing activity of Os-pep. The
levels of p-AMPK, p-IRS-1Tyr 632 and p-PI3K/Akt/GSK3β
(Ser 9) were not elevated after exposure to a low insulin
(10 nmol/L) concentration. However, Os-pep (10 μM) sig-
nificantly activated the p-IRS-1Tyr 632 and p-PI3K/Akt/
GSK3β (Ser 9) pathways through the activation of p-
AMPK, indicating that Os-pep reduced insulin resistance
via an AdipoR1/p-AMPK-dependent mechanism (Fig. 4e).
Moreover, AdipoR1 siRNA and the AMPK inhibitor com-
pound C (Comp. C) (10 μM) inhibited the insulin-
sensitizing effect of Os-pep. Based on these results, Os-pep
induced insulin sensitivity by increasing the levels of p-IRS-
1Tyr 632 and p-PI3K/Akt/GSK3β (Ser 9) through an Adi-
poR1/AMPK-dependent mechanism to exert its beneficial
effects (Fig. 4e). Collectively, the results show that Os-pep
reduced neuronal insulin resistance and activated insulin
signaling in the brain by stimulating AdipoR1/AMPK sig-
naling to exert beneficial effects on AD pathology.
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Os-pep via AdipoR1 restored synaptic functions in mice
with AD-mimicking pathological conditions and in
Adipo−/− mice
To investigate the effect of Os-pep on synaptic function,
we assessed memory-associated pre- and postsynaptic
protein markers. Os-pep (5 μg/g, i.p., on alternating days
for 45 days) remarkably increased pre- and postsynaptic
protein levels in AD (AβO-treated, APP/PS1) and
Adipo−/− mice (Fig. 5a-c). Os-pep (5 μg/g, i.p., on alter-
nating days for 45 days) administration alone in WT
normal mice did not have any detrimental effects on the
pre- and postsynaptic markers, which provides a proof
Fig. 2 Os-pep stimulated AdipoR1/p-AMPK signaling in in vitro AD models. (a) Immunoblotting and quantification of AdipoR1 and p-AMPK levels
in human APPswe/ind-overexpressed SH-SY5Y cells transfected with the AdipoR1 siRNA and treated with Os-pep (10 μM). The data are expressed
as the means ± SEM for the indicated proteins in vitro (n = 5/group), and the number of independent experiments = 3. Significance = ***p < 0.001;
###p < 0.001; Two-way ANOVA followed by Bonferroni’s multiple comparisons test (b) Immunofluorescence reactivity for AdipoR1 (Red: TRITC and
Blue: DAPI, Brightfield; B.F.) in human APPswe/ind-overexpressed SH-SY5Y cells transfected with the AdipoR1 siRNA and treated with Os-pep (10 μM).
Magnified 40X. Scale bar = 20 μm. The data are indicated as the ± SEM for n = 5 images per group, and the number of independent experiments = 3.
Significance = ***p < 0.001; ###p < 0.001; Two-way ANOVA followed by Bonferroni’s multiple comparisons test (c, d) Histograms present ELISA and
immunoassay results for the AdipoR1 and AMPK levels respectively, in vitro cell lysates of human APPswe/ind-overexpressed SH-SY5Y cells expressing
the AdipoR1 siRNA in the presence or absence of the Os-pep dosage (10 μM) for 12 h. The data are expressed as the means ± SEM for
the indicated proteins in vitro (n = 5/group), and the number of independent experiments = 3. Significance = ***p < 0.001; ###p < 0.001;
Two-way ANOVA followed by Bonferroni’s multiple comparisons test
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of principle that chronic Os-pep administration has no
harmful effects (Fig. 5a). Furthermore, to assess mechan-
istically the roles of AdipoR1/AMPK signaling and neur-
onal insulin resistance, we analyzed the two main pre-
and postsynaptic protein markers (synaptophysin
(Synap) and postsynaptic density protein (PSD95), re-
spectively) in human neuronal SH-SY5Y cells overex-
pressing APPswe/ind and expressing AdipoR1 siRNA
and in APPswe/ind-overexpressing SH-SY5YIR cells ex-
posed to AdipoR1 siRNA and treated with Comp. C
(10 μM). Importantly, Os-pep restored and significantly
increased Synap and PSD95 expression in APPswe/ind-
overexpressing SH-SY5Y cells; however, Os-pep did not
restore or increase Synap and PSD95 expression in
APPswe/ind-overexpressing SH-SY5Y cells exposed to
AdipoR1 siRNA (Fig. 5d). Interestingly, when SH-
SY5YIR cells overexpressing APPswe/ind expressed Adi-
poR1 siRNA and were treated with Comp. C, Os-pep
did not increase the levels of Synap and PSD-95 (Fig.
5e).
Next, to test the effect of Os-pep on dendritic com-
plexity and spine density, we designed separate cohort
studies and performed Golgi staining and analyses. In
Fig. 5f, Panel (a), and Fig. S5a, three representative pyr-
amidal neurons are shown, and a remarkable decrease in
the total dendritic length was found in Adipo−/− and
AβO mice. Os-pep (5 μg/g, i.p., on alternating days for
45 days) significantly increased the total dendritic length
(Fig. 5f, Panel (a, b); Fig. S5a, b). Likewise, administration
of Os-pep to Adipo−/− and AβO mice remarkably en-
hanced the complexity of dendrites in the apex and base
region (Fig. 5f, Panel (c); Fig. S5c). Furthermore, we
Fig. 3 Os-pep rescued neuronal insulin resistance via AdipoR1/AMPK signaling in vitro and in vivo AD models and Adipo−/− mice. (a-c)
Immunoblotting and quantification of p-IRS-1 (Ser 636)/ total-IRS-1 and p-IRS-1 (Ser 312)/total-RS-1 levels in the AβO, APP/PS1 and Adipo−/− mice.
The data are expressed as the means ± SEM for the indicated proteins in vivo (n = 8 mice/group) and the number of independent experiments =
3. Significance = **p < 0.01, ***p < 0.001; ###p < 0.001; One-way ANOVA followed by Turkey’s post hoc test. ns, indicated that there is no
significant difference among the control, sham and Os-pep treated groups (d) Double immunofluorescence staining for Aβ (FITC, green) and p-
IRS-1 (Ser 636) (TRITC, red) in the cortex and hippocampus of APP/PS1 mice. The data are expressed as the means ± SEM for n = 5 mice/group,
and the number of independent experiments = 3. Magnification 40x and magnified 40X. Scale bar = 50 μm and 20 μm respectively.
Significance = **p < 0.01, ***p < 0.001; #p < 0.05, ##p < 0.01, ###p < 0.001; One-way ANOVA followed by Turkey’s post hoc test. (e) Immunoblotting
and quantification of p-IRS-1 (Ser 636)/total-IRS-1 and p-IRS-1 (Ser 312)/total-IRS-1 levels in the human APPswe/ind-overexpressed SH-SY5Y cells
transfected with the AdipoR1 siRNA and treated with Os-pep (10 μM). The data are expressed as the means ± SEM for the indicated
proteins in vitro (n = 5/group), and the number of independent experiments = 3. Significance = ***p < 0.001; ###p < 0.001; Two-way ANOVA
followed by Bonferroni’s multiple comparisons test
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observed significantly reduced spine numbers in the
CA1 region of the hippocampus in the Adipo−/− and
AβO mice (Fig. f, Panel (d); Fig. S5d). Notably, a reduced
number of filopodia-like spines were observed in the
Adipo−/− and AβO mice (Fig. 5f, Panel (e); Fig. S5e);
nevertheless, no significant change was observed in the
numbers of thin, stubby and mushroom-like spines.
Interestingly, Os-pep administration to Adipo−/− and
AβO mice significantly increased the total number of
spines and the number of filopodia-like spines. These
results revealed that Os-pep had beneficial effects on
dendrites and spine density in Adipo−/− and AD mice.
We also investigated whether Os-pep modulated syn-
aptic function and plasticity using electrophysiology. In
Fig. 6a, panels (a,b); b, panels (a,b), the results indicated
that LTP was remarkably reduced in slices of the CA1
region of the hippocampus in APP/PS1 and Adipo−/−
mice. Os-pep improved LTP in the APP/PS1 and
Adipo−/− mice (Fig. 6a, panels (b,c); b panels (a,b)). The
percentage increase in EPSCs induced by paired stimuli
is shown for the APP/PS1 and Adipo−/− mice (Fig. 6a,
Fig. 4 Os-pep activated downstream insulin signaling via AdipoR1/AMPK signaling in vitro and in vivo AD models and Adipo−/− mice. (a-c)
Immunoblotting and quantification of p-PI3K/total-PI3K, p-Akt/total-Akt and p-GSK3β (Ser 9)/total-GSK3β levels in the AβO-treated, APP/PS1 and
Adipo−/− mice. The data are expressed as the means ± SEM for the indicated proteins in vivo (n = 8 mice/group) and the number of
independent experiments = 3. Significance = ***p < 0.001; ###p < 0.001; One-way ANOVA followed by Turkey’s post hoc test. ns, indicated that
there is no significant difference among the control, sham and Os-pep treated groups (d) Immunoblotting and quantification of p-AMPK/total-
AMPK, p-IRS-1 (Tyr632)/total-IRS-1, p-PI3K/total-PI3K, p-Akt/total-Akt and p-GSK3β (Ser 9)/total-GSK3β levels in APPswe/ind-overexpressed SH-SY5Y
cells transfected with the AMPK siRNA and treated with Os-pep (10 μM). The data are expressed as the means ± SEM for the indicated proteins in vitro
(n = 5/group), and the number of independent experiments = 3. Significance = *p < 0.05, **p < 0.01 ***p < 0.001; #p < 0.05, ##p < 0.01, ###p < 0.001;
Two-way ANOVA followed by Bonferroni’s multiple comparisons test (e) Immunoblotting and quantification of p-AMPK/total-AMPK, p-IRS-1 (Tyr
632)/total-IRS-1, p-PI3K/total-PI3K, p-Akt/total-Akt and p-GSK3β (Ser 9)/total-GSK3β levels in APPswe/ind-overexpressed SH-SY5Y cells exposed to a
high insulin (1 μM) concentration (SH-SY5YIR), low insulin concentration (10 nM), Os-pep (10 μM) and Comp. C (10 μM) and transfected with the
AdipoR1 siRNA. The data are expressed as the means ± SEM for the indicated proteins in vitro (n = 5/group), and the number of independent
experiments = 3. Significance = *p < 0.05, **p < 0.01 ***p < 0.001; #p < 0.05, ##p < 0.01, ###p < 0.001; Two-way ANOVA followed by Bonferroni’s
multiple comparisons test
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Fig. 5 (See legend on next page.)
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panel (d); b, panel (d)). Furthermore, to validate the
mechanism of the effect of Os-pep on LTP improve-
ments, we determined whether these improvements are
AdipoR1 dependent or not. We designed a separate
group of studies in which we used AβO-treated (sub-
jected to treatment with scramble and functional Adi-
poR1 shRNA) AD mice. As shown in Fig. 6c, panels (a,
b), LTP was significantly attenuated in AβO mice. The
suppression of LTP was almost completely rescued to a
level comparable to that of normal controls by Os-pep
in scramble shRNA-treated AβO mice (Fig. 6c, panel
(d)). Nevertheless, the potentiating effect of Os-pep on
LTP was significantly attenuated by shRNA-mediated si-
lencing of the AdipoR1 gene (Fig. 6c, panels (c, e)),
strongly implying the contribution of AdipoR1 to Os-
pep-induced restoration of LTP. These intriguing results
strongly suggest that Os-pep increases pre- and postsyn-
aptic protein markers as well as enhances LTP in pre-
clinical animal models via activation of AdipoR1
signaling.
The Os-pep dosage regimen improved learning and
memory functions via AdipoR1 in AD and Adipo−/− mice
For the first time in this study, to the best of our know-
ledge, the small 9-amino acid Os-pep, which is consid-
ered an adiponectin-mimetic peptide, was evaluated for
its effect on memory and learning functions in well-
established AβO-treated and APP/PS1 transgenic mouse
models of memory deficits and AD as well as in
Adipo−/− mice; it was recently reported that Adipo−/−
mice have deficits in learning and memory functions
[14, 16]. Following Os-pep regimen (5 μg/g, i.p., on alter-
nating days for 45 days) completion, the mice were eval-
uated in behavioral studies with the MWM and Y-maze
tests. In the MWM tests, we initially observed that Os-
pep enhanced and restored the learning/memory func-
tions of the AβO-injected and APP/PS1 mice as well as
the Adipo−/− mice, as revealed by the decrease in the la-
tency to reach the submerged platform in the training
session (Fig. 7 a-c). Furthermore, the probe test results
indicated that Os-pep significantly improved learning
and memory functions, as more time was spent in the
target quadrant, and there was a significantly increased
number of platform crossings in the AβO-injected, APP/
PS1 and Adipo−/− groups (Fig. 7d-i). Additionally, the
swimming speeds in the training session and the final
day prior to the probe test were not significantly differ-
ent among all groups (Fig. S6a, panels (a-i)). Next, the
Y-maze results indicated that Os-pep significantly in-
creased the percentage of spontaneous alternation be-
haviors in the AβO-injected, APP/PS1 and Adipo−/−
mice (Fig. 7j-l), indicating that Os-pep improved spatial
working memory functions.
To determine the mechanistic influence of Os-pep on
memory functions, we designed a separate group of stud-
ies (AβO-injected mice exposed to scramble shRNA and
shRNA silencing of the AdipoR1 gene). The measurement
of latency during training, the probe test and the spontan-
eous alternation behavior percentage indicated that Os-
pep did not improve spatial learning/memory functions in
the AβO-injected mice exposed to shRNA silencing of the
AdipoR1 gene compared to those in animals that received
the scramble shRNA (Fig. 7m-p). Similarly, the mouse
swimming speeds in the training session and on the 7th
day prior to the probe test were not significantly different
among all groups (Fig. S6b, panels (a-c)). Based on these
observations, Os-pep chronic administration (5 μg/g, i.p.,
on alternating days for 45 days) rescued the memory
(See figure on previous page.)
Fig. 5 Os-pep restored synaptic functions in mice and in vitro with AD-mimicking pathological conditions and Adipo−/− mice. (a-c)
Immunoblotting and quantification of Synap, SNAP-23, SAP102 and PSD95 levels in the AβO, APP/PS1 and Adipo−/− mice respectively. The data
are expressed as the means ± SEM for the indicated proteins in vivo (n = 8 mice/group) and the number of independent experiments = 3.
Significance = ***p < 0.001; ###p < 0.001; One-way ANOVA followed by Turkey’s post hoc test. ns, indicated that there is no significant difference
among the control, sham and Os-pep treated groups (d) Immunoblotting and quantification of the Synap and PSD95 levels in APPswe/ind-
overexpressed SH-SY5Y cells transfected with the AdipoR1 siRNA and treated with Os-pep (10 μM). The data are expressed as the means ± SEM
for the indicated proteins in vitro (n = 5/group), and the number of independent experiments = 3. Significance = ***p < 0.001; ###p < 0.001; Two-
way ANOVA followed by Bonferroni’s multiple comparisons test (e) Immunoblotting and quantification of the Synap and PSD95 levels in
APPswe/ind-overexpressed SH-SY5YIR cells exposed to a high insulin (1 μM) concentration, a low insulin concentration (10 nM), Os-pep (10 μM)
and Comp. C (10 μM) and transfected with the AdipoR1 siRNA. The data are expressed as the means ± SEM for the indicated proteins in vitro
(n = 5/group), and the number of independent experiments = 3. Significance = ***p < 0.01, **p < 0.01; ###p < 0.001; Two-way ANOVA followed by
Bonferroni’s multiple comparisons test. (f) Os-pep regulated dendritic complexity and spine density in the Adipo−/− mice. (f, panel (a)) Indicated
images were the example of the reconstructed hippocampal CA1 region of pyramidal neurons in the WT (Veh), Adipo−/− and Os-pep treated
Adipo−/− (Os-pep). (f, panel (b)) Representative histogram indicated total dendritic length (sum of basal and apical dendrite length) in the
hippocampal CA1 region of the mice. (f, panel (c)) Representative histogram indicated dendritic complexity via using the sholl analysis of
reconstructed pyramidal neurons. (f, panel (d)) Representative images of digitalized hippocampal CA1 pyramidal dendrites from the secondary
branches. (f, panel (e)) Representative histograms indicate the dendritic spines density; including the total number of spines, the number of
filopodia-like, thin, mushroom and stubby spines in the hippocampal CA1 region of brain mice. The data are shown as the mean ± SEM of 45
pyramidal neurons and 300 dendritic segments per groups and the number of independent experiments = 3. Significance = *p < 0.05; #p < 0.05;
One-way ANOVA followed by Turkey’s post hoc test
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deficits associated with aberrant neuronal metabolic-
associated AD pathology via activation of AdipoR1-
dependent processes, and these results corroborate and
validate the above in vivo and in vitro biochemical and
immunohistological results.
Acute bolus dosages and chronic optimized dosages have
no major adverse effects on mice
To optimize and analyze the toxicity and effective
dose of Os-pep, we performed a separate group of
studies in order to assess signs of systemic toxicity,
such as head tilt, tremor, changes in physical activity
and squinting, for 1 week in normal WT mice
Fig. 6 Os-pep restores LTP ability in the APP/PS1, Adipo−/− and AβO-treated mice via AdipoR1 dependent manner. (a, panels (a-c); b, panels (a-
c)) Upper trace, a representative EPSC trace before and after LTP was induced by paired stimuli in the CA1 regions of the hippocampi of Veh-
injected WT or Veh-injected APP/PS1 and Adipo−/− mice respectively. Lower trace, an average time course of EPSCs before and after LTP was
induced by paired stimuli in the CA1 regions of the hippocampi of Veh-injected WT, APP/PS1 and Adipo−/− mice, as well as Os-pep-treated APP/
PS1 and Adipo−/− mice. (a, panel (d); b, panel (d)) A summary of the effect of the Os-pep treatment on LTP induction in APP/PS1 and Adipo−/−
mice respectively. (c, panels (a-d)) Upper trace, a representative EPSC trace before and after LTP was induced by TBS stimuli in the CA1 regions
of the hippocampi of Veh-injected WT or Veh-injected AβO. Lower trace, an average time course of EPSCs before and after LTP was induced by
paired stimuli in the CA1 regions of the hippocampi of Veh-injected WT or Veh-injected AβO mice, as well as Os-pep-treated AβO-injected mice
subjected to scramble shRNA and shRNA mediating silencing of AdipoR1 gene. (c, panel (e)) A summary of the effect of the Os-pep dosage on
LTP induction in Veh-injected WT or Veh-injected AβO mice, as well as Os-pep-treated AβO mice subjected to scramble and shRNA mediating
silencing of AdipoR1 gene. The data are expressed as the means ± SEM for n = 5–6 mice per group and the number of independent
experiments = 3. Significance = *p < 0.05, **p < 0.01 ***p < 0.001; #p < 0.05, ##p < 0.01, ###p < 0.001; One-way ANOVA followed by Turkey’s post
hoc test
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injected i.p. with bolus doses of Os-pep (10, 20, 30,
40 and 50 mg/kg) to investigate the safety profile of
bolus doses of Os-pep. We observed a profile indicat-
ing that Os-pep was safe, and no toxicity was ob-
served in any of the mice treated with bolus doses
(data not shown).
When Os-pep was administered chronically at an opti-
mized dosage (5 μg/g, i.p., on alternating days for 45 days) to
all mice, the immunoblotting results showed that Os-pep
didn’t induce any harmful effects on any cellular signaling
(e.g. AdipoR1/AMPK, insulin resistance and downstream in-
sulin signaling) in brain as well as synaptic functions.
In addition to the observations and results described
above (Fig. S3a-d; Fig. S4a-d), Os-pep regulated the bio-
chemical parameters associated with metabolic disorder
and AD in the serum of APP/PS1, HFD and Adipo−/−
Fig. 7 Os-pep via AdipoR1 dependently improved the learning and memory of AD, Adipo−/− and AdipoR1 shRNA mice. MWM and Y-maze assays
were used to assess the spatial working memory and cognitive functions in the AD mouse models and in the Adipo−/− mice. Thirteen mice from
each group were used for the behavioral evaluation. (a-c) The mean escape latency (sec) to reach the hidden platform during training of the
AβO-treated, APP/PS1 and Adipo−/− mice. (d-i) The time spent in the target quadrant and number of platform crossings during the probe test of
the AβO-treated, APP/PS1 and Adipo−/− mice. (j-l) Histograms present the percentage of spontaneous alternation behaviors by the AβO-treated,
APP/PS1 and Adipo−/− mice respectively during the Y-maze test. (m) The mean escape latency (sec) to reach the hidden platform during training
of the AβO-treated (subjected to scramble and functional AdipoR1 shRNA). (n, o) The time spent in the target quadrant and number of platform
crossings during the probe test of the AβO-treated (subjected to scramble and functional AdipoR1 shRNA). (p) Histograms present the
percentage of spontaneous alternation behaviors by the AβO-treated (subjected to scramble and functional AdipoR1 shRNA) during the Y-maze
test. The escape latencies in the behavioral tests were analyzed using a two-way ANOVA, with training days as the repeated measurements.
Graphs show the means ± SEM for the mice (13 mice per group) and the number of independent experiments = 3. Significance = *p < 0.05, **p <
0.01 ***p < 0.001; #p < 0.05, ##p < 0.01, ###p < 0.001; One-way ANOVA followed by Turkey’s post hoc test. ns, indicated that there is no significant
difference among the control, sham and Os-pep treated groups
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mice. These results suggested that Os-pep did not in-
duce liver or kidney dysfunction. All the observations of
mice treated with bolus doses and chronic dosage regi-
mens proved that Os-pep has no observable side effects
in animal models and acts as a safe adiponectin-mimetic
peptide. However, further biochemical and molecular-
based studies of the peripheral organs will be assessed
for the acute and chronic administration of Os-pep.
Neuroprotective and pharmacokinetic profile of Os-pep
Furthermore, to assess the neuroprotective profile of Os-
pep in vitro, we performed ApoTox-Glo™ Triplex assays
in SH-SY5Y and HT22 cells. The results of the ApoTox-
Glo™ Triplex assay in SH-SY5Y and HT22 cells showed
that cell viability was reduced, whereas cytotoxicity and
the activation of caspases3/7 were increased after AβO
(1 μM) exposure for 12 h. However, cotreatment with
varying concentrations (0.5, 1, 5 and 10 μM) of Os-pep
reduced the neurotoxic effects of AβO (1 μM); notably,
the 10 μM concentration was more effective and signifi-
cantly reduced AβO (1 μM) neurotoxicity by increasing
cell viability and decreasing cytotoxicity and caspase3/7
activation (Fig. 8a, panels (a-c)). We then analyzed the
protective effects of Os-pep (10 μM) on AβO (1 μM)-
treated SH-SY5Y and HT22 cells transfected with Adi-
poR1 siRNA using ApoTox-Glo™ Triplex assays. The cell
viability, cytotoxicity and caspases3/7 detection results in-
dicated that Os-pep (10 μM) did not reduce the AβO-
induced toxicity in the AdipoR1 siRNA-transfected SH-
SY5Y and HT22 cells (Fig. 8a, panels (d-f)).
Next, to assess the neuroprotective effects of Os-
pep in vivo, we evaluated the levels of apoptotic and
neurodegenerative markers, e.g., activated caspase-3 and
cleaved poly (ADP-ribose) polymerase-1 (PARP-1), by
immunoblotting. Os-pep administration (5 μg/g, i.p., on
alternating days for 45 days) significantly decreased the
activated caspase-3 and cleaved PARP-1 levels in the
APP/PS1 mice (Fig. 8b). Notably, and most importantly,
cleaved PARP-1 was detected by stripping the PVDF
membrane used for the detection of AdipoR1, so these
results confirmed that AdipoR1 activation by Os-pep
plays a key role in protection against neurodegenerative
diseases. Further studies are required to explore this
mechanism. Furthermore, based on these results, Os-pep
exerted a beneficial protective effect by activating Adi-
poR1, which is consistent with other studies, suggesting
that AdipoR1 activation prevents neurodegeneration
[11–16, 38, 39].
Next, we performed pharmacokinetic analysis, and Os-
pep was degraded according to first-order kinetics. After
2 h, 53% of the initial concentration remained. The Os-
pep half-life (t1/2) was calculated to be approximately 2 h
(Fig. 8c). The 2 h t1/2 of Os-pep indicated that Os-pep is
a relatively stable peptide compared to other bioactive
peptides, affirming its stability. Furthermore, we deter-
mined the ability of Os-pep to cross the blood-brain bar-
rier (BBB) and reach the brain. Based on confocal
microscopy, FITC-conjugated Os-pep reached the brain
after an i.p. injection (Fig. 8d). In addition, we also ana-
lyzed the cellular uptake of Os-pep using FITC-
conjugated Os-pep in brain endothelial (bEnd3) cells
(Fig. 8e). Based on these in vitro and in vivo results, the
small 9-amino acid Os-pep represents a safe and stable
neuroprotective adiponectin-mimetic novel peptide that
crosses the BBB and reaches the brain, where it stimu-
lates AdipoR1 and prevents memory deficits in aberrant
brain metabolism-associated AD.
Discussion
According to several recent studies, the reduction of adi-
ponectin and AdipoR1 signaling in the brain has been
implicated in metabolic-associated AD. The reduction of
adiponectin levels and adiponectin receptor signaling
may be emerging factors that increase the risk of AD as-
sociated with metabolic dysfunction. Subjects with adi-
ponectin and AdipoR1 signaling deficiencies developed
brain insulin resistance and impaired downstream insu-
lin signaling, which mediates AD pathology [9, 14–16,
22]. For the past decade, our group has investigated
whether the phytopolypeptide osmotin (a homolog of
mammalian adiponectin) reduces AD pathology. How-
ever, osmotin and adiponectin are limited as therapeu-
tics for use in further translational and clinical studies
because of their large size. Therefore, we extended our
approach by using the osmotin-based small adiponectin-
mimetic novel nonapeptide Os-pep. Furthermore, to the
best of our knowledge, for the first time, we explored
the in-depth mechanistic biological and therapeutic ef-
fects of the adiponectin-mimetic novel nonapeptide on
rigorous in vitro and in vivo models of AD and Adipo−/−
mice. We verified the results in AβO-treated, AβO- and
scramble and functional AdipoR1 shRNA-treated, and
APP/PS1 mice, in in vitro AβO and APPswe/ind overex-
pression AD models, and in HFD and Adipo−/− mice.
Many studies have investigated whether AβO induces
brain metabolic dysfunction, which induces neuronal in-
sulin resistance in the brains of AD patients and in in vi-
tro and animal AD models; dysregulation of insulin
signaling through the phosphorylation of p-IRS-
1Ser636/312 induces synaptic and memory impairments [8,
9]. Suppression of AdipoR1/AMPK signaling in Adipo−/−
mice leads to the development of insulin resistance in
the brain and subsequent development of AD pathology
[15, 16]. Notably, aberrant neuronal insulin signaling
and brain insulin resistance increase Aβ generation by
enhancing amyloidogenic APP processing, and this may
lead to a vicious cycle. Aβ impairs insulin signaling and,
in turn, reduces p-PI3K/Akt/GSK3βSer9 signaling.
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Fig. 8 (See legend on next page.)
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Activated insulin and p-PI3K/Akt/GSK3βSer9 signaling
have been shown to play key roles in the reduction of
Aβ and tau pathology [49–51]. Deficits in AdipoR1 sig-
naling in chronic adiponectin-deficient mouse models
were recently shown to mediate AD pathology, leading
to an increase in p-IRS-1Ser 636/312/616 and a decrease in
p-IRS-1Tyr632 levels. These changes result in the down-
regulation of the p-PI3K/Akt/p-GSK3βSer9 pathway,
leading to GSK3β activation and the subsequent escal-
ation of Aβ production. Furthermore, adiponectin in-
duces AdipoR1/AMPK signaling to increase insulin
sensitivity through the activation of p-IRS-1Tyr632 and
downstream insulin signaling via stimulation of the p-
PI3K/Akt/GSK3βSer9 pathway [9, 11, 15, 16]. Therefore,
adiponectin, adiponectin-mimetic peptides and AdipoR1
have been implicated in various metabolic diseases and
are key targets for the prevention of neurological disor-
ders. AdipoR1 is a primary target in AD, as studies from
our group and other groups have recently reported the
reduced expression of AdipoR1 in APP/PS1 and
Adipo−/− mice. Most importantly, we also found reduced
AdipoR1 expression in the aged human AD brain. Thus,
AdipoR1 activation reduces AD neuropathology and has
been considered an emerging therapeutic approach for
the treatment of AD [14–16, 21, 38–40]. AMPK, a key
energy sensor and well-known downstream kinase of
AdipoR1, is activated both in vivo and in vitro by adipo-
nectin and other agents that mimic adiponectin via Adi-
poR1. AMPK exerts a neuroprotective effect against
various neurodegenerative injury, and reduced AMPK
expression leads to neurodegeneration. In contrast,
AMPK activation regulates neurodegeneration [35, 36,
52–54]. Activated AMPK regulates aberrant brain me-
tabolism and reduces insulin resistance [14–16, 55, 56].
Furthermore, these results are supported by those of a
recent study showing that reduced AdipoR1/AMPK sig-
naling, and neuronal insulin resistance are associated
with AD pathology in adiponectin-deficient mice. Ac-
cording to the results from a few recent and exciting
studies, activation of AdipoR1/AMPK signaling in the
brain may be a beneficial therapeutic approach for the
reduction of AD pathology [15, 56, 57]. The in vitro
AβO-exposed and APPswe/ind-overexpressing cells and
the in vivo AD and Adipo−/− mice showed reduced levels
of AdipoR1/p-APMK, suggesting that brain metabolism
and energy are implicated in neuronal insulin resistance
associated with adiponectin deficiency. Intriguingly, Os-
pep, as an adiponectin-mimetic nonapeptide, had benefi-
cial effects by activating AdipoR1/AMPK signaling to
prevent neuronal insulin resistance by reducing p-IRS-
1Ser636/312 levels and stimulating the p-IRS-1Tyr632 and p-
PI3K/Akt/GSK3βSer9 pathways through an AdipoR1/
AMPK-dependent mechanism.
Synaptic dysfunction is a complex process that oc-
curs either directly through AβO or indirectly
through other intermediate parameters that contribute
to synaptic deficits [58, 59]. Based on accumulating
evidence, deficits in pre- and postsynaptic protein
markers are implicated in memory decline in AD. Im-
portantly, AβO is known to suppress LTP and induce
memory dysfunction [59–61]. In brain metabolism,
AD reduces synaptic density by impairing and inhibit-
ing insulin signaling in the brain. However, activation
of insulin signaling and reduction of neuronal insulin
resistance in the brain prevents synaptic/memory defi-
cits in AD [62, 63]. Recently, brain neuronal insulin
resistance was reported to trigger synaptic plasticity
dysfunction and reduce LTP and memory function in
HFD mice [64]. AdipoR1 activation was recently
shown to increase the levels of pre- and postsynaptic
proteins and synaptic protection in HFD mice
in in vivo and in vitro AD models as well as in
Adipo−/− mice [14–16]. Furthermore, our recent stud-
ies indicated that activated AdipoR1 regulated neur-
onal outgrowth and synaptic complexity in AD [40].
Most importantly, in this study, Os-pep, as an
adiponectin-mimetic nonapeptide that functions as a
ligand for AdipoR1 to trigger AdipoR1/AMPK signal-
ing, subsequently decreased neuronal insulin resist-
ance and increased pre- and postsynaptic protein
markers as well spine morphogenesis in the hippo-
campal neuronal CA1 region of Adipo−/− and AβO
(See figure on previous page.)
Fig. 8 Neuroprotective and pharmacokinetic profile of Os-pep in the in vivo and in vitro studies. (a, panels (a-c)) Apotox-Glo Triplex assays of
the cell viability, cytotoxicity and activated caspase3/7 levels in SH-SY5Y and HT22 cells treated with AβO (1 μM) and different concentrations of
Os-pep. (a, panels (d-f)) Apotox-Glo Triplex assays of the cell viability, cytotoxicity and activated caspase3/7 levels in SH-SY5Y and HT22 cells
transfected with the AdipoR1 siRNA and treated with AβO (1 μM) and Os-pep (10 μM). Data are expressed as means ± SEM for three independent
experiments. Significance = *p < 0.05, **p < 0.01 ***p < 0.001; #p < 0.05, ##p < 0.01, ###p < 0.001; One-way ANOVA followed by Turkey’s post hoc
test. (b) Immunoblotting and quantification of activated caspase-3 and cleaved PARP-1 levels in the APP/PS1 mice. Data are expressed as the
means ± SEM for the indicated proteins (n = 8 mice/group), and the number of independent experiments = 3. The data presented in this figure
are normalized to control values. Significance = **p < 0.01; ##p < 0.01; One-way ANOVA followed by Turkey’s post hoc test. (c-e) Pharmacokinetic
profile of Os-pep. (c) Stability of Os-pep in mouse plasma. The Os-pep concentration at 0 min is set to 100%. Bars represent SD (standard
deviation) (n = 3) for triplicate samples. (d) Confocal microscopy images of the Veh-injected WT and Os-pep-FITC-injected WT mice. The number
of mice = 3/group and number of independent experiments = 3. Magnification: 10X. Scale bar = 100 μm. (e) Confocal microscopy images of the
bEnd cells exposed to bidistilled water and Os-pep-FITC. The number of independent experiments = 3. Magnified 10X. Scale bar = 100 μm
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mice. Moreover, we observed for the first time that
the dosage regimen of Os-pep improved LTP and
cognitive functions such as learning and memory via
the activation of AdipoR1 in normal AβO-injected
and transgenic APP/PS1 mouse models of AD and in
Adipo−/− mice, as measured using the MWM and Y-
maze tests.
Adiponectin and AdipoR signaling were recently
shown to play a promising role in various metabolic and
age-associated neuropathological disorders because adi-
ponectin enhances peripheral and central insulin sensi-
tivity and prevents insulin resistance [65–68].
Importantly, AdipoR1 has been implicated in the regula-
tion of AD-related neuropathology. Adiponectin acti-
vates AdipoR1 and prevents neuroinflammation and
shows protective activities in various metabolic disor-
ders. Hence, adipokines and their receptors, particularly
adiponectin and its mimetic peptides via AdipoR1 acti-
vation, represent an emerging, novel and attractive po-
tential therapeutic target for the prevention of AD and
other neuropathological disorders [14–16, 21, 35–37,
69–73]. However, adipokines, particularly adiponectin
and its receptor, should be thoroughly monitored for
translation-based studies because of recent findings and
epidemiological studies that reported that an excess adi-
ponectin level is associated with lethal effects, such as
circulatory disorders (chronic heart failure & chronic
kidney failure), as well as other undesirable effects, such
as weight loss, low skeletal muscle mass/density, and
physical functioning impairment, which ultimately lead
to morbidity and mortality [26–31].
Conclusion
In summary, our intriguing in vitro and in vivo findings
strongly indicated that an adiponectin-mimetic novel
nonapeptide crossed the BBB and had a good safety and
protection profile, regulated neuronal metabolism-
associated AdipoR1/AMPK targets, prevented neuronal
insulin resistance, enhanced downstream insulin signal-
ing, and consequently improved synaptic plasticity and
memory functions in AD and Adipo−/− mice. Previously
studies demonstrated that osmotin derived this Os-pep
[43, 44], interacts with the mammalian adiponectin rec-
ognition site on AdipoR1 as well as in our pilot studies
and the finding in this study demonstrated that Os-pep
induced beneficial and therapeutic effects via interacting
primarily with AdipoR1, which subsequently activate
AdipoR1 and its downstream signaling. However, it is
worth to mention here that the Os-pep might has the
potential to activate AdipoR2 or activate or antagonize
other non-specific receptors and transcription factors,
which will be further investigated in computational ap-
proaches as well as in vitro and in vivo models of other
peripheral-and brain metabolic disorders, and other
neurodegenerative diseases. Recently, the therapeutic ap-
proach of using peptides to prevent neurological disor-
ders has emerged, and its advantages over the use of
small molecules have been reported because peptides
display higher potency, specificity and fewer side effects
in other targets in the body. In addition, peptide therapy
is economical, nontoxic and safe. All of these parameters
and the increased accessibility via easy customization
and synthesis in a well-controlled system make the use
of peptides an ideal and rational therapeutic strategy for
the development of drugs against AD. Based on our
rigorous results, we believe and suggest that Os-pep is
an emerging, interesting and valuable novel peptide-
based therapeutic candidate for translational research to
halt and treat AD. Of note, considering the adiponectin
paradox and the very recent amyloidogenic evolvability
theory [24, 25, 74], we suggest that future translational
studies of this adiponectin-mimetic nonapeptide be per-
formed, and the therapeutic effects of Os-pep on Aβ ag-
gregation and the hyperphosphorylation of tau proteins
as well as the regulation of cellular homeostasis will be
tested in animal models at different stages of AD, such
as transgenic mice that are 12 ~ 24months old as well as
SAMP8 (senescence-accelerated) mice as late-onset
(sporadic) AD models. Similarly, we recommend that
Os-pep-based therapeutic approaches be validated for
the treatment of other neurodegenerative disorders asso-
ciated with aberrant metabolism.
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